Mumbai, Jan. 7 -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), and Fortress Biotech, Inc. (Nasdaq: FBIO) (Fortress) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and Priority review Sentynl's New Drug Application (NDA) for CUTX-101, the product candidate for the treatment of Menkes disease.

Published by HT Digital Content Services with permission from Capital Market....